BHEL pays 40% dividend to shareholders for 2016-17With this, it has maintained its impeccable track record of earning profits and rewarding investors by paying dividends uninterruptedly for...
BHEL not worried about CEA draft reportBHEL was also targeting stranded power projects and said recently one project worth Rs 8,000 crore was started.
Bhel to reduce dependency on thermal power plant marketBhel has invested Rs 300 crore to enhance its solar photo voltaic cell making capability to 225 MW as part of its plan to shed thermal busi...
Bhel launches Kosti thermal power plant in SudanPower equipment maker Bhel announced the inauguration of 500 MW Kosti thermal power plant in Sudan, the largest in that country.
Atul Sobti to be Bharat Heavy Electricals Ltd's next CMDBharat Heavy Electricals Ltd today said Atul Sobti will be its next chairman and managing director and will take charge on or after January...
'When differences can’t be resolved, you must move on'For Ranbaxy, troubles seem to be far from over. Atul Sobti, managing director and chief executive of the company, resigned on Thursday, quo...
- Arun Sawhney to replace Atul Sobti as Ranbaxy CEO
Sobti’s exit comes at a time, when the company seems to have seen the worst of its regulatory problems in the US which has dragged its reve...
- Atul Sobti to step down as Ranbaxy CEO & MD?
Arun Sawhney, president global pharmaceutical business is seen as a contendor to take over Sobti's position. Sobti was more of an interim C...
- Ranbaxy expects $100 mn revenues from South Africa by 2010
Ranbaxy Laboratories on Thursday said it expects revenues of $100 million in 2010 from operations in South Africa.
- Daiichi-Ranbaxy synergy plan delayed, announcement by Mar
Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo's proposal to unveil a three-year plan for exploiting synergies in operations t...
- Issues with USFDA to take long to resolve: Ranbaxy
Ranbaxy is in talks with the US Food and Drug Administration (USFDA)to sort out issues related to generic drugs but the matter is likely to...
- Ranbaxy-Daiichi working on a 3-year plan for synergising ops
Ranbaxy Laboratories and its Japanese parent Daiichi Sankyo are working on a three-year plan for exploiting synergies in operations to enha...
- Ranbaxy cuts pay package to one-third for new chief
The country's top drugmaker, Ranbaxy, has proposed an annual pay package of Rs 6 crore for its new CEO and MD Atul Sobti, but his remunerat...
- Ranbaxy forays into protein supplement market
Ranbaxy Laboratories has forayed into the protein supplement market in India, by launching its product under the brand Revitalite, a compan...
It would be foolish to say I had no ambitions: Atul SobtiAtul Sobti has been appointed the CEO and MD of India’s largest drug maker at a time when it is going through the most turbulent phase of i...
- Ranbaxy elevates Atul Sobti as COO
Ranbaxy Laboratories on Monday announced the appointment of Atul Sobti as the company’s chief operating officer with effect from January 1,...
- Atul Sobti joins Ranbaxy as new COO
Global pharmaceutical major, Ranbaxy Labs on Monday announced the appointment of Atul Sobti as the Chief Operating Officer from January 1, ...